Nikolay Boychev

Dr. Nikolay Boychev

Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
VYVincent Yeung
Vincent Yeung
NBNikolay Boychev
Nikolay Boychev
Wissam FarhatWissam Farhat
Wissam Farhat
DNDimitrios Ntentakis
Dimitrios Ntentakis
AHAudrey E.K. Hutcheon
Audrey E.K. Hutcheon
JCJoseph B. Ciolino
Joseph B. Ciolino
Communication between cells and the microenvironment is a complex, yet crucial, element in the development and progression of varied physiological and pathological processes. Accumulating evidence in different disease models highlights roles of extracellular vesicles (EVs), either in modulating cell signaling paracrine mechanism(s) or harnessing their therapeutic moiety. Of interest, the human cornea functions as a refractive and transparent barrier that protects the intraocular elements from the external environment. Corneal trauma at the ocular surface may lead to diminished corneal clarity and detrimental effects on visual acuity. The aberrant activation of corneal stromal cells, which leads to myofibroblast differentiation and a disorganized extracellular matrix is a central biological process that may result in corneal fibrosis/scarring. In recent years, understanding the pathological and therapeutic EV mechanism(s) of action in the context of corneal biology has been a topic of increasing interest. In this review, we describe the clinical relevance of corneal fibrosis/scarring and how corneal stromal cells contribute to wound repair and their generation of the stromal haze. Furthermore, we will delve into EV characterization, their subtypes, and the pathological and therapeutic roles they play in corneal scarring/fibrosis.

5 August 2022 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
Wissam FarhatWissam Farhat
Wissam Farhat
VYVincent Yeung
Vincent Yeung
ARAmy Ross
Amy Ross
FKFrancesca Kahale
Francesca Kahale
NBNikolay Boychev
Nikolay Boychev
JCJoseph B. Ciolino
Joseph B. Ciolino
An overview of the key developments in biomaterials as platforms for delivering chemotherapy for the management of retinoblastoma is provided in this review.

1 June 2016 in Contact Lens and Anterior Eye
Verified
Journal Article
Open access
NBNikolay Boychev
Nikolay Boychev
DLDeborah S. Laughton
Deborah S. Laughton
GBGulshan Bharwani
Gulshan Bharwani
HGHafsa Ghuman
Hafsa Ghuman
James S. WolffsohnJames S. Wolffsohn
James S. Wolffsohn
To investigate how initial HEMA and silicone-hydrogel (SiHy) contact lens fit on insertion, which informs prescribing decisions, reflect end of day fit. Thirty participants (aged 22.9±4.9 years) were fitted contralaterally with HEMA and SiHy contact lenses. Corneal topography and tear break-up time were assessed pre-lens wear. Centration, lag, post-blink movement during up-gaze and push-up recovery speed were recorded after 5,10,20min and 8h of contact lens wear by a digital slit-lamp biomicroscope camera, along with reported comfort. Lens fit metrics were analysed using bespoke software. Comfort and centration were similar with the HEMA and SiHy lenses (p>0.05), but comfort decreased with time (p0.05), but was slower with SiHy after 8h wear (p=0.016). Lens movement on blink and push-up recovery speed was predictive of the movement after 8h of wear after 10-20min SiHy wear, but after 5 to 20min of HEMA lens wear. A HEMA or SiHy contact lens with poor movement on blink/push-up after at least 10min after insertion should be rejected.

Verified
Journal Article
Open access
PDF file
VYVincent Yeung
Vincent Yeung
NBNikolay Boychev
Nikolay Boychev
LKLevi N Kanu
Levi N Kanu
VNVeronica Ng
Veronica Ng
ARAmy Ross
Amy Ross
JCJoseph B. Ciolino
Joseph B. Ciolino
Communication between the different layers of the cornea (epithelium and stroma) is a complex, yet crucial element in the corneal healing process. Upon corneal injury, it has been reported that the bi-directional cross talk between the epithelium and stroma via the vesicular secretome, namely, extracellular vesicles (EVs), can lead to accelerated wound closure upon injury. However, the distinct protein markers of EVs derived from human corneal epithelial (HCE) cells, keratocytes (HCKs), fibroblasts (HCFs), and myofibroblasts (HCMs) remain poorly understood. All EVs were enriched for CD81 and showed increased expression levels of ITGAV and FN1 in HCM-EVs compared to HCE- and HCF-EVs. All EVs were negative for GM130 and showed minimal differences in biophysical properties (particle concentration, median particle size, and zeta potential). At the proteomic level, we show that HCM-EVs are enriched with proteins associated with fibrosis pathways, such as COL6A1, COL6A2, MMP1, MMP2, TIMP1, and TIMP2, compared to HCE-, HCK-, and HCF-EVs. Interestingly, HCE-EVs express proteins involved with the EIF-2 signaling pathway (stress-induced signals to regulate mRNA translation), such as RPS21, RALB, EIF3H, RALA, and others, compared to HCK-, HCF-, and HCM-EVs. In this study, we isolated EVs from cell-conditioned media from HCE, HCKs, HCFs, and HCMs and characterized their biophysical and protein composition by Western blot, nanoparticle tracking analysis, and proteomics. This study supports the view that EVs from the corneal epithelium and stroma have a distinct molecular composition and may provide novel protein markers to distinguish the difference between HCE-, HCK-, HCF-, and HCM-EVs.

19 December 2022 in Cornea
Verified
Journal Article
Closed access
NBNikolay Boychev
Nikolay Boychev
SASofia De Arrigunaga
Sofia De Arrigunaga
YZYan Zhao
Yan Zhao
JCJoseph B. Ciolino
Joseph B. Ciolino
Purpose: The aim of the study is to investigate US-based ophthalmologists’ preferred corneal transplant techniques and postoperative steroid regimen. Methods: Ophthalmologists attending the 2021 Cornea and Eye Banking Forum and/or Cornea Subspecialty Day were surveyed in person. Results: Ninety-two ophthalmologists with a median of 13 years (range of 1–35; mean of 14.5; ±9.05 mean ± SD) of experience as attending clinicians were surveyed. One hundred percent of the surgeons performed penetrating keratoplasty, which was followed by 96.7% for Descemet stripping endothelial keratoplasty, 90.2% for Descemet membrane endothelial keratoplasty, and 72.8% for deep anterior lamellar keratoplasty. Prednisolone 1% for postoperative care was the preferred choice across all surveyed keratoplasty techniques and postsurgery time intervals. All surgeons reported steroid administration frequency of 4 times a day in the first month and once a day after 12 months postkeratoplasty. To manage ocular hypertension after corneal transplantation, the leading approach was adding a glaucoma medication (44.6%), and beta-adrenergic antagonists were ranked as the most preferred choice by 59 (66.3%) of the respondents. For graft rejection after corneal transplantation, topical steroids (79.8%) were the initial treatment of choice with hourly administration being the most common frequency prescribed (87.4%). Most surgeons either agreed or strongly agreed (78.4%) that a randomized clinical trial evaluating the safety and efficacy of different steroid regimens after corneal transplantation would influence their clinical decision making. Conclusions: Prednisolone remains the predominantly used steroid across different keratoplasties. Steroid regimens are similar for non–high-risk penetrating keratoplasty, Descemet membrane endothelial keratoplasty, Descemet stripping endothelial keratoplasty, and deep anterior lamellar keratoplasty. To treat graft rejection, surgeons tend to initially add a glaucoma medication than to reduce the potency or frequency of the steroid.

8 December 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LCLin Chen
Lin Chen
LKLiangju Kuang
Liangju Kuang
ARAmy Ross
Amy Ross
Wissam FarhatWissam Farhat
Wissam Farhat
NBNikolay Boychev
Nikolay Boychev
JCJoseph B. Ciolino
Joseph B. Ciolino
This study aimed to develop a miltefosine-eluting contact lens (MLF-CL) device that would allow sustained and localized miltefosine release for the treatment of Acanthamoeba keratitis. MLF-CLs were produced in three different miltefosine doses by solvent-casting a thin miltefosine-polymer film around the periphery of a methafilcon hydrogel, which was then lathed into a contact lens. During seven days of in vitro testing, all three formulations demonstrated sustained release from the lens at theoretically therapeutic levels. Based on the physicochemical characterization of MLF-CLs, MLF-CL’s physical properties are not significantly different from commercial contact lenses in terms of light transmittance, water content and wettability. MLF-CLs possessed a slight reduction in compression modulus that was attributed to the inclusion of polymer-drug films but still remain within the optimal range of soft contact lenses. In cytotoxicity studies, MLF-CL indicated up to 91% viability, which decreased proportionally as miltefosine loading increased. A three-day biocompatibility test on New Zealand White rabbits revealed no impact of MLF-CLs on the corneal tissue. The MLF-CLs provided sustained in vitro release of miltefosine for a week while maintaining comparable physical features to a commercial contact lens. MLF-CL has a promising potential to be used as a successful treatment method for Acanthamoeba keratitis.